1

Title:
99m Tc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mouse.
Running foot line:
Sensitivity of 99m Tc-cAbVCAM1-5 imaging
Author's names and affiliations:
Alexis Broisat 1,2* , PhD; Jakub Toczek 1,2* , PhD; Laurent Dumas Indeed, in a mouse model of atherosclerosis, 99m Tc-cAbVCAM1-5specifically bound to VCAM-1 positive lesions, thereby allowing their identification on SPECT images. The purpose of the present study was to investigate 99m Tc-cAbVCAM1-5 imaging sensitivity using a reference statin therapy.
Methods.ThirtyApoE-deficient mice were fed a western-type diet. First, the relationship between the level of VCAM-1 expression and 99m
Tc-cAbVCAM1-5 uptake was evaluated in 18 mice using immunohistochemistry and autoradiography (ARG). Second, longitudinal SPECT/CT imaging was performed on control (n=9) or atorvastatin-treated mice (0.01% w/w, n=9).
Results.
99m
Tc-cAbVCAM1-5 uptake in atherosclerotic lesionscorrelated with the level of VCAM-1 expression (P<0.05).Atorvastatin exerted significant anti-atherogeniceffects, and 99m Tc-cAbVCAM1-5 lesion uptake was significantly reduced in 35 weeks-old atorvastatintreated mice, as indicated by ex vivo gamma-well counting and ARG (p<0.05). Contrast-CT based SPECT imaging quantification was reproducible (inter experimenter ICC = 0.97, intra experimenter ICC = 0.90), and yielded results that were highly correlated with tracer biodistribution (r=0.83; P<0.0001). Therefore, reduced 99m Tc-cAbVCAM1-5 uptake in atorvastatin-treated mice was successfully monitored non-invasively by SPECT/CT imaging (0.87 ± 0.06 %ID/cm 3 vs 1.11 ± 0.09 %ID/cm 3 in control group, P<0.05).
Conclusions.
Tc-cAbVCAM1-5 imaging allowed the specific, sensitive and reproducible quantification of VCAM-1 expression in mice atherosclerotic lesions. Tc-cAbVCAM1-5 therefore exhibits suitable characteristics for the evaluation of novel anti-atherogenic agents..
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Introduction.
Atherosclerosis constitutes a worldwide health challenge(1 Tc-cAbVCAM1-5 for both human and murine VCAM-1 therefore makes the tracerpotentially suitable for clinical translation (10) .
The main objective of the present study was to investigate the sensitivity of Indeed, high sensitivity is a key requirement for VP imaging as well as for the preclinical assessment of the efficacy of novel anti-atherogenic therapies. In accordance with the major role of inflammatory processes in the development of VP, the anti-inflammatory effect of new therapeutic agents targeting at the lipid profile such as cholesteriylesterasetransfert protein inhibitors is currently being investigated (11) . In addition, therapeutic interventions aimed at directly targeting the inflammatory process are also under evaluation(3) using drugs such as methotrexate, canakinumab or losmapimod (12) (13) (14) . A specific and sensitive imaging agent targeting at the inflammatory process occurring in atherosclerotic lesions would therefore be of great relevance for the evaluation of novel anti-atherogenic agents.
Statins are well established and widely used therapeutics in clinical practice, and atorvastatin has previously been employed for the evaluation of new imaging agents in mouse models of atherosclerosis (15) (16) (17) .In the present preclinical study, atorvastatin was used in order to evaluate the potential of 99m Tc-cAbVCAM1-5for the monitoring of treatment efficacy in ApoE deficient mice.
Methods
Animal model
All experimental procedures werein accordance with institutional guidelines and approved by the Animal Care & Use committee (ComEth) of the University ofGrenoble.
Twelve (12) 40-wks old female ApoE-deficient mice (Charles River) fed a western type diet were used for the ex vivo comparison between 99m Tc-cAbVCAM1-5 uptake in atherosclerotic lesions and VCAM-1 expression.
Eighteen female ApoE-deficient mice were used for the non invasive evaluation of a reference therapy.At the age of 15 weeks, mice were either fed a western diet (control group, n=9) or a western diet supplemented with a reference therapy (0.01% atorvastatin) (treated group, n=9). In these two groups, average food consumption and animal weight were assessed weekly and blood sampling was performed before and 10 weeks following the onset of western diet for total cholesterol determination (BioMerieux). The effect of the statin therapy on 99m
Tc-cAbVCAM1-5 uptake in atherosclerotic lesions was evaluated in vivo using longitudinal SPECT/CT imaging on 25 and 35 weeks-old mice, and ex vivo by gamma well counting (GWC) and autoradiography.
Radiolabeling.
cAbVCAM1-5 labeling with 99m
Tc was performed as previously described (10) . Briefly, Tc-cAbVCAM1-5 uptake in atherosclerotic lesions and VCAM-1 expression level were determined using autoradiographicimagingand immunohistochemistry , respectively (n=12). Three (3) hours following intraveinousinjection of 37±3MBq (mean±SD), mice were euthanized using CO 2 .
The aortic arch was cleaned in 10% formalin (Sigma) under a binocular (Discovery V8, Zeiss), embedded in optimal cutting temperature (OCT) medium and frozen in40°Cisopentane. Serial 20μm or 8μm-thick adjacent slices were obtained for Autoradiography and immunohistochemistry, respectively (HM 505E, Microm).For the purpose of this study, longitudinal orientation was preferred for it allowed simultaneous examination of several lesions, located in the ascending aorta, small curvature of the aortic arch, innominate, left common carotid and left subclavian arteries, and descending aorta.
Autoradiography
Autoradiographieswere acquiredusing overnight exposure with a phosphor-Imager (BAS-5000, Fujifilm). All slices were then stained using standard hematoxylin-eosinsafrantrichrome staining (HES), digitalized, andHES and autoradiographicimages were coregistered using GIMP2 and ImageJsoftwares. Regions of interest (ROIs) were drawn on atherosclerotic lesions based on HES staining. Internal references with known amounts of radioactivity were used to express tracer activity as percent injected dose per gram (%ID/g)following background and decay correction.
Immunohistochemistry VCAM-1 immunostaining(sc-1504, santa-Cruz) was performedas previously described(10)onslices adjacent to those used for autoradiography / HES. VCAM-1 expression level in atherosclerotic lesions (n=94) was ranked as low, moderate or strong by a trained observer blinded to the autoradiographicimages. This analysis was reproduced 2 months later by the same observer in order to assess the reproducibility of themethodology.
Non invasive evaluation of a reference therapy.
SPECT/CT imaging
SPECT/CT acquisitions were performed two hours following an intravenous injection of 55±5
Tc-cAbVCAM1-5.The mice were anesthetized using isoflurane 1.5% in a 1:1 mixture of room air and oxygen, and then placed in a temperature-controlled bed for SPECT/CT acquisitions focused on the thoracic region (nanoSPECT, Bioscan). First, the helicoidal SPECT acquisition was performed with 4 heads equipped with multi-pinholes collimators (9 x 1.4 mm diameter pinhole per head) using 24 projections and 45 min of acquisition. Then, a fast, 1.5min-long CT acquisition was performed immediately following retro-orbital injection of 150µl of a vascular contrast agent (Hexabrix), using the following acquisition parameters: 65kvp, 180 projections and 500ms per projection. Contrast-CT and SPECT acquisitions were reconstructed fused and quantified using dedicated software (InVivoScope).
SPECT/CT quantification
Contrast-CT based SPECT quantification was performed blinded to the SPECT images.
Briefly, ) and uptake in atherosclerotic lesions was defined as the maximumvalue fromquantification of 4 VOIs.
Moreover, in order to assess the inter and intra-observer variability, 35 weeks SPECT images were further quantified by 3 additional independent experimenters, and this quantification was reproduced 2 weeks later by one of the experimenters.
Ex vivo quantification
Following SPECT/CT imaging, anesthetized mice were euthanized using CO 2 Tc-cAbVCAM1-5 uptake was then expressed as a %ID present in the analyzed slice ("total uptake").
Statistical analysis.
All results are presented as mean±s.e.m. F-test was employed for variances comparisons.
Student t, Mann &Witney U, Pearson,intraclass coefficient (ICC) and Kappa tests were employed forpaired/unpaired datasets with equal variances, unpaired datasets with unequal variances,correlation analysis,and inter/intra experimenters variability, respectively.
Differences were considered significant for P<0.05.
Results
99m Tc-cAbVCAM1-5 uptake versus VCAM-1 expression.
Heterogeneous VCAM-1 expression levels were observed following immunostainingof longitudinal slices from the aortic arch of Apo-deficient mice ( figure 1A&C ). VCAM-1 was expressed by endothelial as well as intra-plaque cells. Intra-observer ranking of VCAM-1 expression level was found to be reproducible (kappa=0.70). Robust 99m Tc-cAbVCAM1-5 uptake was observed following autoradiographicimaging of VCAM-1 positive lesions ( figure   1B&D ). Autoradiographyquantification confirmed the relationship between 99m Tc-cAbVCAM1-5 uptake and the level of VCAM-1 expression ( figure 1E ). Indeed, a graded tracer uptakeof 1.4 ± 0.2, 2.5 ± 0.2 and 3. 2 ± 0.3 %ID/g was observed in low, moderate and strong VCAM-1 expressing lesions, respectively (P<0.001 between low and moderate or strong, and P = 0.029 between moderate and high).
Non invasive evaluation of a reference therapy
Lesion extension.
The results are presented in Table 1 and Figure 1 . Similar cholesterol levels were observed between treated and control animals prior to switching from chow to western dietcontaining , P = 0.011) ( Table 1 and suppl. fig. 1 ). Finally, modest variations in VCAM-1 expression in the aortic sinus were observed between control and treated animals following immunohistochemistry(suppl. fig. 1 ).
In vivo SPECT/CT imaging. 
Ex vivo gamma-well counting.
99m Tc-cAbVCAM1-5 biodistribution is presented in Table 2 . Tc-cAbVCAM1-5 uptake in atorvastatin-treated animals was significantly decreased by 24.1 % in the ascending aorta of atorvastatin-treated animals (0.9 ± 0.1 vs 1.2 ± 0.1 %ID/g, P = 0.015). The tracer was mainly eliminated through the kidneys (138.7 ± 8.6 %ID/g) with minimal uptake in all other investigated tissues (< 2 %ID/g) with the exception of lymphoid organs. Indeed, tracer uptake in the spleen, thymus, bone marrow and lymph node was of 8.8 ± 0.7; 2.1 ± 0.2; 4.0 ± 0.4 and 2.8 ± 0.3 %ID/g, respectively.
Exvivo autoradiography.
In both groups, robust 99m Tc-cAbVCAM1-5 uptake in atherosclerotic lesions was readily observable at the level of the aortic sinus (suppl. fig. 1 A-D 
Comparison between SPECT/CT, autoradiography, and gamma-well counting data
Further data analysis indicated that SPECT/CT quantification was strongly correlated to ex 
Discussion
Atorvastatin significantly reduced lesion extension in the aortic sinus of ApoE-deficient mice, and this effect was successfully monitored non-invasively using 99m Tc-cAbVCAM1-5 molecular imaging with high reproducibility. 99m Tc-cAbVCAM1-5 is therefore a specific, sensitive and reproducible tool for the imaging of VCAM-1 expression in murine atherosclerotic lesions.
Effect of statin therapy.The anti-atherosclerotic effects of statins are mainly mediated by their cholesterol-lowering properties leading to reduced plaque volume (18) . In addition, statins also exert pleiotropic effects which go beyond the drop in plasma cholesterol and which mainly result in an inhibition of inflammatory processes responsible for vulnerable plaque development (19, 20) . However, depending on the dose &duration of the treatment and on study design, the reduction in plasma cholesterol, plaque volume and inflammatory markers are not always consistently or concomitantly observed in experimental studies.
Indeed, in an ApoE-deficient mouse model of carotid artery lesions induced by perivascular collar placement, Bot and coll. observed that a low dose of atorvastatin (0.003%w/w) significantly reduced lesion size by 40% despite no reduction in total plasma cholesterol or macrophage positive areas (15) . Conversely, a twelve week atorvastatin treatment (1 mg/kg/day) resulted in a significant reduction in the circulating inflammatory markers
Interleukin-6 and Monocyte Chemoattractant Protein-1 as well as macrophage infiltration in aortic lesions of apoE-deficientmice despite no significant change in plasma cholesterol and plaque area (21) .
The western-type diet-fed apoE-deficient mice that were used in the present study had a mean total blood cholesterol level of 85.5±8.1 mmol/L, in good accordance with the 28-114 mmol/L range reported on a similar model by Nakashima and coll (22) . Supplementation of the western-type diet with 0.01% w/w atorvastatin resulted in an expected administered dose of 10mg/kg/day (16) . Atorvastatin significantly decreased total cholesterol by 29% and lesion size by 40%. These results are in accordance with the range of atorvastatin-induced modifications reported by other groups (16, 17) . Modest changes in the lesional expression of VCAM-1 were observed in atorvastatin-treated animals, in contrast with other studies showing a significant 30-80% reduction in VCAM-1 expression (16, 17, 23) . However, Nachtigal and coll found no significant change in VCAM-1 lesion expression in double knockout, LDLR -/-ApoE -/-mice in the presence of atorvastatin at a similar dose to that used in the present study (24) .
Overall, atorvastatin administered at a dose of 0.01% w/w for 20 weeks to ApoE-deficient mice fed a western-type diet therefore had significant anti-atherogenic effects that allowed the evaluation of the potential of 99m Tc-cAbVCAM1-5 for treatment effect monitoring. 
Sensitivity of
